Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Prognostic significance of ST3GAL-1 expression in patients with clear cell renal cell carcinoma

Authors: Qi Bai, Li Liu, Yu Xia, Qilai Long, Jiajun Wang, Jiejie Xu, Jianming Guo

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Aberrant sialylated carbohydrate synthesis is frequently noted in various cancers. Sialyltransferase ST3GAL-1, which adds a sialic acid in an α-2,3 linkage to Gal β1,3 GalNAc, preforms an important role in modulating cellular behaviors. However, little is known about prognostic significance of ST3GAL-1 in clear cell renal cell carcinoma (ccRCC). In this study, we aimed to investigate the prognostic significance of sialyltransferase ST3GAL-1 and its correlation with clinical outcomes in patients with ccRCC.

Methods

A total of 286 patients who underwent nephrectomy between 2005 and 2007 in a single academic center were recruited. Immunohistochemical staining was performed on tissue microarrays to assess the expression level. Kaplan-Meier method and Cox proportional hazard model were applied to assess the prognostic value of ST3GAL-1. Nomograms were generated as prediction model for overall survival and disease free survival at 5 and 8 years after nephrectomy.

Results

The present results show high expression of ST3GAL-1 is associated with reduced overall survival (p = 0.013) and disease free survival (p = 0.004). In multivariate cox analyses, ST3GAL-1 was defined as an independent prognostic factor for overall survival (p = 0.006) and disease free survival (p = 0.001). After incorporation into the University of California Integrated Staging System (UISS) intermediate/high risk group for non-metastatic ccRCC, ST3GAL-1 could further distinguish patient with dismal prognosis (p = 0.015 and 0.002 for OS and DFS respectively). The nomograms revealed better predictive accuracy in predicting 5- and 8- year overall survival and disease free survival than the TNM stage alone.

Conclusions

ST3GAL-1 is an independent adverse prognostic factor for recurrence and survival of patients with ccRCC.
Literature
1.
2.
Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:49–56.CrossRef
3.
Stewart GD, O’Mahony FC, Powles T, Riddick ACP, Harrison DJ, Faratian D. What can molecular pathology contribute to the management of renal cell carcinoma? Nat Rev Urol. 2011;8(5):255–65.CrossRefPubMed
4.
Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20(23):4559–66.CrossRefPubMed
5.
Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: An International Multicenter Study. J Clin Oncol. 2004;22(16):3316–22.CrossRefPubMed
6.
Eichelberg C, Junker K, Ljungberg B, Moch H. Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol. 2009;55(4):851–63.CrossRefPubMed
7.
Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol. 2011;60(4):644–61.CrossRefPubMed
8.
Hakomori SI. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res. 1989;52:257–331.CrossRefPubMed
9.
Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P. The human sialyltransferase family. Biochimie. 2001;83(8):727–37.CrossRefPubMed
10.
Schneider F, Kemmner W, Haensch W, Franke G, Gretschel S, Karsten U, et al. Overexpression of sialyltransferase CMP-sialic Acid: Gal beta 1,3GalNAc-R alpha 6-sialyltransferase is related to poor patient survival in human colorectal carcinomas. Cancer Res. 2001;61(11):4605–11.PubMed
11.
Cohen AM, Allalouf D, Djaldetti M, Weigl K, Lehrer N, Levinsky H. Sialyltransferase activity in plasma-cells of multiple-myeloma. Eur J Haematol. 1989;43(3):191–4.CrossRefPubMed
12.
Dimitroff CJ, Pera P, Dall’Olio F, Matta KL, Chandrasekaran EV, Lau JTY, et al. Cell surface N-acetylneuraminic acid alpha 2,3-galactoside-dependent intercellular adhesion of human colon cancer cells. Biochem Bioph Res Co. 1999;256(3):631–6.CrossRef
13.
Ganzinger U, Deutsch E. Serum sialyltransferase levels as a parameter in the diagnosis and follow-up of gastrointestinal tumors. Cancer Res. 1980;40(4):1300–4.PubMed
14.
Schultz MJ, Swindall AF, Bellis SL. Regulation of the metastatic cell phenotype by sialylated glycans. Cancer Metast Rev. 2012;31(3-4):501–18.CrossRef
15.
Videira PA, Correia M, Malagolini N, Crespo HJ, Ligeiro D, Calais FM, et al. ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer. 2009;9:357.PubMedCentralCrossRefPubMed
16.
Picco G, Julien S, Brockhausen I, Beatson R, Antonopoulos A, Haslam S, et al. Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology. 2010;20(10):1241–50.PubMedCentralCrossRefPubMed
17.
Burchell J, Poulsom R, Hanby A, Whitehouse C, Cooper L, Clausen H, et al. An alpha 2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology. 1999;9(12):1307–11.CrossRefPubMed
18.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.CrossRefPubMed
19.
Leibovich BC, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma - A stratification tool for prospective clinical trials. Cancer-Am Cancer Soc. 2003;97(7):1663–71.
20.
21.
Guo HB, Nairn A, Harris K, Randolph M, Alvarez-Manilla G, Moremen K, et al. Loss of expression of N-acetylglucosaminyltransferase Va results in altered gene expression of glycosyltransferases and galectins. Febs Lett. 2008;582(4):527–35.PubMedCentralCrossRefPubMed
22.
Paulson JC, Blixt O, Collins BE. Sweet spots in functional glycomics. Nat Chem Biol. 2006;2(5):238–48.CrossRefPubMed
23.
Varki A, Schauer R. Sialic acids. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, editors. Essentials of glycobiology. 2nd ed. NY: Cold Spring Harbor; 2009.
24.
Bull C, Stoel MA, den Brok MH, Adema GJ. Sialic acids sweeten a Tumor’s life. Cancer Res. 2014;74(12):3199–204.CrossRefPubMed
25.
Sakuma K, Aoki M, Kannagi R. Transcription factors c-Myc and CDX2 mediate E-selectin ligand expression in colon cancer cells undergoing EGF/bFGF-induced epithelial-mesenchymal transition. Proc Natl Acad Sci U S A. 2012;109(20):7776–81.PubMedCentralCrossRefPubMed
26.
Duan LL, Guo P, Zhang Y, Chen HL. Regulation of metastasis-suppressive gene nm23-H1 on glycosyl-transferases involved in the synthesis of sialyl lewis antigens. J Cell Biochem. 2005;94(6):1248–57.CrossRefPubMed
27.
Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, et al. Increased expression of sialyl lewis(X) antigen correlates with poor survival in patients with colorectal-carcinoma - clinicopathological and immunohistochemical study. Cancer Res. 1993;53(15):3632–7.PubMed
28.
Koike T, Kimura N, Miyazaki K, Yabuta T, Kumamoto K, Takenoshita S, et al. Hypoxia induces adhesion molecules on cancer cells: a missing link between Warburg effect and induction of selectin-ligand carbohydrates. Proc Natl Acad Sci U S A. 2004;101(21):8132–7.PubMedCentralCrossRefPubMed
29.
Nakamori S, Kameyama M, Imaoka S, Furukawa H, Ishikawa O, Sasaki Y, et al. Involvement of carbohydrate antigen sialyl Lewis(x) in colorectal cancer metastasis. Dis Colon Rectum. 1997;40(4):420–31.CrossRefPubMed
30.
Krause T, Turner GA. Are selectins involved in metastasis? Clin Exp Metastas. 1999;17(3):183–92.CrossRef
31.
Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Pictures in molecular medicine - three-dimensional visualization of intravascular tumor cells in mice. Trends Mol Med. 2001;7(8):377–7.CrossRefPubMed
32.
Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005;5(7):526–42.CrossRefPubMed
33.
Rillahan CD, Antonopoulos A, Lefort CT, Sonon R, Azadi P, Ley K, et al. Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat Chem Biol. 2012;8(7):661–8.PubMedCentralCrossRefPubMed
34.
Bull C, Boltje TJ, Wassink M, de Graaf AMA, van Delft FL, den Brok MH, et al. Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. Mol Cancer Ther. 2013;12(10):1935–46.CrossRefPubMed
Metadata
Title
Prognostic significance of ST3GAL-1 expression in patients with clear cell renal cell carcinoma
Authors
Qi Bai
Li Liu
Yu Xia
Qilai Long
Jiajun Wang
Jiejie Xu
Jianming Guo
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1906-5

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

Awareness of preventive medication among women at high risk for breast cancer and their willingness to consider transdermal or oral tamoxifen: a focus group study

Research article

The prognostic significance of lymphovascular invasion in patients with resectable gastric cancer: a large retrospective study from Southern China

Research article

Socioeconomic disparities in breast cancer incidence and survival among parous women: findings from a population-based cohort, 1964–2008

Research article

P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement

Research article

The role of c-Src in the invasion and metastasis of hepatocellular carcinoma cells induced by association of cell surface GRP78 with activated α2M

Research article

Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits